Basic Principles and Clinical Applications of CRISPR-Based Genome Editing

키워드

참고문헌 (74)

1. Jinek M, "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity", Science, 337, pp.816~821 (2012)
2. Kim H, "A guide to genome engineering with programmable nucleases", Nat Rev Genet, 15, pp.321~334 (2014)
3. Cong L, "Multiplex genome engineering using CRISPR", Cas systems, 2013, pp.339, 819~823
4. Mali P, "RNAguided human genome engineering via Cas9", Science, 339, pp.823~826 (2013)
5. Ran FA, "In vivo genome editing using Staphylococcus aureus Cas9", Nature, 520, pp.186~191 (2015)
6. Hou Z, "Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis", Proc Natl Acad Sci U S A, 110, pp.15644~15649 (2013)
7. Kim E, "In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni", Nat Commun, 8, pp.14500~ (2017)
8. Abudayyeh OO, "RNA targeting with CRISPR-Cas13", Nature, 550, pp.280~284 (2017)
9. Slaymaker IM, "Rationally engineered Cas9 nucleases with improved specificity", Science, 351, pp.84~88 (2016)
10. Kleinstiver BP, "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects", Nature, 529, pp.490~495 (2016)
11. Chen JS, "Enhanced proofreading governs CRISPR-Cas9targeting accuracy", Nature, 550, pp.407~410 (2017)
12. Casini A, "A highly specific SpCas9 variant is identified by in vivo screening in yeast", Nat Biotechnol, 36, pp.265~271 (2018)
13. Kim N, "Prediction of the sequence-specific cleavage activity of Cas9 variants", Nat Biotechnol, 38, pp.1328~1336 (2020)
14. Hu JH, "Evolved Cas9 variants with broad PAM compatibility and high DNA specificity", Nature, 556, pp.57~63 (2018)
15. Nishimasu H, "Engineered CRISPR-Cas9 nuclease with expanded targeting space", Science, 361, pp.1259~1262 (2018)
16. Walton RT, "Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants", Science, 368, pp.290~296 (2020)
17. Komor AC, "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage", Nature, 533, pp.420~424 (2016)
18. Gaudelli NM, "Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage", Nature, 551, pp.464~471 (2017)
19. Rees HA, "Base editing : precision chemistry on the genome and transcriptome of living cells", Nat Rev Genet, 19, pp.770~788 (2018)
20. Anzalone AV, "Search-and-replace genome editing without doublestrand breaks or donor DNA", Nature, 576, pp.149~157 (2019)
21. Wang D, "CRISPR-based therapeutic genome editing : strategies and in vivo delivery by AAV vectors", Cell, 181, pp.136~150 (2020)
22. Truong DJ, "Development of an intein-mediated split-Cas9 system for gene therapy", Nucleic Acids Res, 43, pp.6450~6458 (2015)
23. Levy JM, "Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses", Nat Biomed Eng, 4, pp.97~110 (2020)
24. Liu P, "Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice", Nat Commun, 12, pp.2121~ (2021)
25. Hanlon KS, "High levels of AAV vector integration into CRISPR-induced DNA breaks", Nat Commun, 10, pp.4439~ (2019)
26. Kuranda K, "Exposure to wild-type AAV drives distinct capsid immunity profiles in humans", J Clin Invest, 128, pp.5267~5279 (2018)
27. Xu Y, "Key considerations in designing CRISPR", Cas9-carrying nanoparticles for therapeutic genome editing, 2020, pp.12, 21001~21014
28. Duan L, "Nanoparticle delivery of CRISPR", Cas9 for genome editing, 2021, pp.12, 673286~
29. Gillmore JD, "CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis", N Engl J Med, 385, pp.493~502 (2021)
30. Xu L, "CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia", N Engl J Med, 381, pp.1240~1247 (2019)
31. Frangoul H, "CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia", N Engl J Med, 384, pp.252~260 (2021)
32. Corbacioglu S, "Initial safety and efficacy results with a single dose of autologous CRISPR-Cas9 modified CD34+ hematopoietic stem and progenitor cells in transfusion-dependent β-thalassemia and sickle cell disease", EHA25 Virtual : EHA Library, S280~ (2020)
33. Frangoul H, "Safety and efficacy of CTX001 in patients with transfusion-dependent β-thalassemia and sickle cell disease:early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-Cas9-modified CD34+ hematopoietic stem and progenitor cells", 62nd ASH Annual Meeting and Exposition:American Society of Hematology, pp.4~ (2020)
34. Stadtmauer EA, "CRISPR-engineered T cells in patients with refractory cancer", Science, 367, pp.eaba7365~ (2020)
35. Lu Y, "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-smallcell lung cancer", Nat Med, 26, pp.732~740 (2020)
36. Jing Z, "Safety and activity of programmed cell death-1 gene knockout engineered t cells in patients with previously treated advanced esophageal squamous cell carcinoma : an open-label, single-arm phase I study", 2018 ASCO Annual Meeting I: American Society of Clinical Oncology, pp.3054~ (2018)
37. Maeder ML, "Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10", Nat Med, 25, pp.229~233 (2019)
38. Jo DH, "CRISPRCas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis", Sci Adv (2019)
39. Jang HK, "High-purity production and precise editing of DNA base editing ribonucleoproteins", Sci Adv, 7, pp.eabg2661~ (2021)
40. "Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis" (2021)[URL]
41. Hyewon Jang, "Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases", Nature Biomedical Engineering, 6(2), pp.181~194 (2021), Springer Science and Business Media LLC[DOI]
42. Smalley E, "First AAV gene therapy poised for landmark approval", Nat Biotechnol, 35, pp.998~999 (2017)
43. Yu W, "Nrl knockdown by AAV-delivered CRISPR", Cas9 prevents retinal degeneration in mice, 2017, pp.8, 14716~
44. Moreno AM, "In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation", Mol Ther, 26, pp.1818~1827 (2018)
45. Goossens R, "Intronic SMCHD1 variants in FSHD : testing the potential for CRISPR-Cas9 genome editing", J Med Genet, 56, pp.828~837 (2019)
46. Wu WH, "CRISPR repair reveals causative mutation in a preclinical model of retinitis pigmentosa", Mol Ther, 24, pp.1388~1394 (2016)
47. Vagni P, "Gene editing preserves visual functions in a mouse model of retinal degeneration", Front Neurosci, 13, pp.945~ (2019)
48. Latella MC, "In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR", Cas9 in the mouse retina, 2016, pp.5, e389~
49. Bakondi B, "In vivo CRISPR", Cas9 gene editing corrects retinal dystrophy in the S334ter-3rat model of autosomal dominant retinitis pigmentosa, 2016, pp.24, 556~563
50. Hu S, "In vivo CRISPR", Cas9-mediated genome editing mitigates photoreceptor degeneration in a mouse model of X-linked retinitis pigmentosa, 2020, pp.61, 31~
51. Yin H, "Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype", Nat Biotechnol, 32, pp.551~553 (2014)
52. Ibraheim R, "Allin-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo", Genome Biol, 19, pp.137~ (2018)
53. Agudelo D, "Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9", Genome Res, 30, pp.107~117 (2020)
54. Song CQ, "Adenine base editing in an adult mouse model of tyrosinaemia", Nat Biomed Eng, 4, pp.125~130 (2020)
55. Yang L, "Amelioration of an inherited metabolic liver disease through creation of a de novo start codon by cytidine base editing", Mol Ther, 28, pp.1673~1683 (2020)
56. Villiger L, "Treatment of a metabolic liver disease by in vivo genome base editing in adult mice", Nat Med, 24, pp.1519~1525 (2018)
57. Richards DY, "AAV-mediated CRISPR", Cas9 gene editing in murine phenylketonuria, 2020, pp.17, 234~245
58. Shuming Yin, "Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor", Science China Life Sciences, 65(4), pp.718~730 (2020), Springer Science and Business Media LLC[DOI]
59. Yang Y, "A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice", Nat Biotechnol, 34, pp.334~338 (2016)
60. Long C, "Prevention of muscular dystrophy in mice by CRISPR", Cas9-mediated editing of germline DNA, 2014, pp.345, 1184~1188
61. Nelson CE, "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy", Science, 351, pp.403~407 (2016)
62. Tabebordbar M, "In vivo gene editing in dystrophic mouse muscle and muscle stem cells", Science, 351, pp.407~411 (2016)
63. Bengtsson NE, "Muscle-specific CRISPR", Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy, 2017, pp.8, 14454~
64. Amoasii L, "Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy", Science, 362, pp.86~91 (2018)
65. Moretti A, "Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy", Nat Med, 26, pp.207~214 (2020)
66. Ryu SM, "Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy", Nat Biotechnol, 36, pp.536~539 (2018)
67. Gaj T, "In vivo genome editing improves motor function and extends survival in a mouse model of ALS", Sci Adv, 3, pp.eaar3952~ (2017)
68. Arnaoutova I, "Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR", Cas9-based gene editing, 2021, pp.29, 1602~1610
69. Koblan LW, "In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice", Nature, 589, pp.608~614 (2021)
70. Zhao L, "Exploration of CRISPR", Cas9-based gene editing as therapy for osteoarthritis, 2019, pp.78, 676~682
71. Sun H, "CRISPR", Cas9 mediated deletion of the angiotensinogen gene reduces hypertension : a potential for cure?, 2021, pp.77, 1990~2000
72. Wan T, "Microneedle-assisted genome editing : a transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders", Sci Adv, 7, pp.eabe2888~ (2021)
73. Guyon A, "Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro", Mol Ther Nucleic Acids, 24, pp.253~263 (2021)
74. Park H, "In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease", Nat Neurosci, 22, pp.524~528 (2019)

관련 논문AI추천